MARKET

IMMP

IMMP

Immutep
NASDAQ
2.950
+0.090
+3.15%
After Hours: 2.990 +0.04 +1.36% 18:59 01/02 EST
OPEN
2.930
PREV CLOSE
2.860
HIGH
2.980
LOW
2.830
VOLUME
159.17K
TURNOVER
--
52 WEEK HIGH
3.530
52 WEEK LOW
1.320
MARKET CAP
434.75M
P/E (TTM)
-10.6383
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at IMMP last week (1222-1226)?
Weekly Report · 12/29/2025 10:00
Immutep Reports Positive Phase I Data for First-in-Class Autoimmune Antibody IMP761
TipRanks · 12/23/2025 11:30
Why Wall Street Is Watching Immutep's Experimental Autoimmune Treatment Closely
Benzinga · 12/22/2025 17:59
Immutep announces update on IMP761 from Phase I study
TipRanks · 12/22/2025 13:15
Immutep Announces Update From Placebo-Controlled, Double-Blind First-In-Human Phase I Study In Healthy Participants Evaluating IMP761, LAG-3 Agonist Antibody For Autoimmune Diseases
Benzinga · 12/22/2025 13:03
IMMUTEP LTD - TRIAL TO CONTINUE WITH UPDATES EXPECTED IN 1H CY2026
Reuters · 12/22/2025 13:00
IMMUTEP ANNOUNCES POSITIVE UPDATE ON IMP761, A FIRST-IN-CLASS LAG-3 AGONIST ANTIBODY FOR AUTOIMMUNE DISEASES, FROM PHASE I STUDY
Reuters · 12/22/2025 13:00
Weekly Report: what happened at IMMP last week (1215-1219)?
Weekly Report · 12/22/2025 10:00
More
About IMMP
Immutep Limited is an Australia-based late-stage biotechnology company. The Company is focused on developing novel immunotherapies for cancer and autoimmune disease. It is focused on advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Its lead clinical candidate is eftilagimod alfa (efti or IMP321) for the treatment of different types of cancers. Efti is the Company’s first-in-class novel immunotherapy that directly activates the immune system to fight cancer, which is under evaluation in TACTI-004 (KEYNOTE-F91), a registrational Phase III trial for the first-line therapy of advanced or metastatic non-small cell lung cancer. Its second in-house product candidate (IMP761) which is in clinical development for the treatment of autoimmune disease, a third product candidate, IMP731, a depleting antibody that could remove T cells involved in autoimmunity.

Webull offers Immutep Ltd - ADR stock information, including NASDAQ: IMMP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMMP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMMP stock methods without spending real money on the virtual paper trading platform.